Thromboxane A2 mediates lung vasoconstriction but not permeability after endotoxin

Area of Science:

• Pharmacology
• Physiology
• Critical Care Medicine

Background:

• Endotoxemia causes significant hemodynamic alterations and increased lung permeability.
• Thromboxane (Tx) is implicated in the pathophysiology of endotoxemia.
• Selective thromboxane synthetase inhibitors offer a potential therapeutic strategy.

Purpose of the Study:

• To evaluate the effects of dazoxiben, a selective thromboxane synthetase inhibitor, on systemic and pulmonary hemodynamics, eicosanoid levels, and lung permeability in a goat model of endotoxemia.
• To determine if inhibiting thromboxane synthesis can mitigate the adverse effects of endotoxin exposure.

Main Methods:

• Awake goats with lung lymph fistulae were infused with Escherichia coli endotoxin.
• Animals were either untreated or pretreated with dazoxiben (bolus and infusion).
• Systemic and pulmonary hemodynamics, plasma thromboxane B2 (TxB2), and lung lymph flow (QL) were monitored.

Main Results:

• Untreated goats showed peak increases in pulmonary artery pressure (Ppa), wedge pressure (Pw), and decreased cardiac output (Qt) coinciding with elevated TxB2 and increased QL.
• Dazoxiben treatment significantly reduced increases in Ppa and Pw, with transient decreases in Qt.
• While QL increased in treated animals, the elevation was less pronounced than in untreated animals, though lymph-plasma protein ratios increased.
• Plasma prostaglandin F2 alpha and 6-keto-PGF1 alpha levels were elevated post-endotoxin, with higher values in the dazoxiben group.

Conclusions:

• Selective inhibition of thromboxane synthesis by dazoxiben ameliorates many adverse hemodynamic consequences of endotoxemia in goats.
• Dazoxiben does not prevent the increase in lung permeability induced by endotoxin.
• Further research may explore combined therapeutic strategies for endotoxemia.